IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No. : Unassigned Confirmation

No.

First Named Inventor : Denis Claude ROY

Filed : Herewith TC/A.U. : Unassigned Examiner : Unassigned

Docket No. : 029049.57806US

Customer No. : 23911

Title : Immunologic Compounds for Prevention, Protection,

Prophylaxis of Treatment of Immunological Disorders,

Infections and Cancer

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R § § 1.97 AND 1.98

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure under 37 C.F.R. § 1.56, the attached Form PTO/SB/08 lists documents which the Examiner may deem relevant to patentability of the claims of the above-identified application.

I. Time Period of Submission

This Information Disclosure Statement is submitted:

∑ 1) no later than three months from the application's filing date or 2) before the mailing date of the first Office Action on the merits (whichever is later) or 3) before a first Office Action after the filing of a Request for Continued Examination, and therefore no statement under 37 C.F.R. § 1.97(e) or fee under 37 C.F.R.§ 1.17(p) is required.
2) after the later of three months from the application's filing date and the mailing date of the first Office Action on the merits, but before a Final Office Action, a Notice of Allowance, or an action closing prosecution (Exparte Quayle), (whichever is earlier), and therefore Applicant is filing concurrently herewith:
a Statement under 37 C.F.R. § 1.97(e); or a fee in the amount of \$180.00 under 37 C.F.R. § 1.17(p).

3) after either a Final Office Action or a Notice of Allowance, but before payment of the Issue Fee, and therefore Applicant is submitting herewith:
a Statement under 37 C.F.R. § 1.97(e); and
a fee in the amount of \$180.00 under 37 C.F.R. § 1.17(p).
II. Statement Under 37 C.F.R. § 1.97(e)
I hereby state that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; or
Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to my knowledge after making a reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this Information Disclosure Statement; or
III. Statement under 37 C.F.R. § 1.704(d) I hereby state that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart application and that this communication was not received by any individual designated in 37 C.F.R. § 1.56(c) more than thirty days prior to the filing of this Information Disclosure Statement.
IV. Submission of Non-English Language Documents
The following is a concise explanation of relevance of the non- English language documents listed in the attached Form PTO/SB/08:
The relevance of document(s) to the subject matter of the present invention is/are provided in the specification of the above-identified application.
Corresponding foreign or international report(s) citing document(s), together with an English-language version(s) (if not already in English) of that portion of the report(s) indicating the degree of relevance found by the foreign office(s) is/are submitted.
English language family member publication(s) of document(s) is/are noted on Form PTO/SB/08.

	English lan	iguage abstrac	ct(s) is	/are submitted t	for document(s)
 is/are su	English tra bmitted here		f the	foreign langua	ge document(s)
	Applicant	submits	the	following	explanations:

V. Relevance

Documents A1-A4 and A10-A12 were cited as being relevant in the International Application, PCT/CA2004/002070 filed December 2, 2005. A copy of the International Search Report setting forth the portion of each reference which the Examiner considered relevant is attached hereto in English. The relevance of documents A5-A9 to the subject matter of the present invention is/are provided in the specification of the above-identified application.

The submission of the listed documents is not intended as an admission that any such document constitutes prior art against the claims of the present application. Applicant does not waive any right to take any action that would be appropriate to antedate or otherwise remove any listed document as a competent reference against the claims of the present application.

If necessary, this paper should be considered as an authorization to charge Deposit Account 05-1323, Attorney Docket No.: 029049.57806US, for the fee set forth in 37 C.F.R. § 1.17(p).

Respectfully submitted,

June 5, 2006

J. D. Evans

Registration No. 26,269

Christopher T. McWhinney Registration No. 42,875

CROWELL & MORING LLP Intellectual Property Group P.O. Box 14300 Washington, DC 20044-4300 Telephone No.: (202) 624-2500 Facsimile No.: (202) 628-8844 JDE:CTM:mdm (2781324)

MODIFIED PTO/SB/08 (08-00) Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCION of the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Hujitoci.							
	Substitute for	form 1449B/	PTO	Complete if Known 15 Q1 7 1 8			
	INFORMATIO	N DISCLO	SURE	Application Number	Unassigned		
	STATEMENT	BY APPLI	CANT	Filing Date	Herewith		
	Data Cubasitt	-d. l	2006	First Named Inventor	Denis Claude ROY et al.		
	Date Submitte	ea: June 5,	2006	Group Art Unit	同的nasanned PIIII () 5 IIIN /IIIIh		
	(use as many sh	neets as ne	cessary)	Examiner Name	Unassigned		
Sheet	1	of	2	Attorney Docket Number	029049.57806US		

U.S. PATENT DOCUMENTS							
Examiner Initials*		U.S. Patent Document		N (D) (A) (A)	Date of Publication of	Pages, Columns, Lines, Where Relevant	
	Cite No. ¹	Number	Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear	
	A1	5,773,460	В	GABOURY et al.	06-30-1998		

Examiner	Cite	F	oreign Patent D	ocument	Name of Patentee or	Date of Publication of Cited Document	Pages, Columns, Lines, Where Relevant	
Initials*	No.1	Office		Kind Code ⁵ (if known)	Applicant of Cited Documents	MM-DD-YYYY	Passages or Relevant Figures Appear	Т
	A2	wo	02/079183	A1	THERATECHNOLOGIES INC.	03-27-2002		
	А3	wo	01/24824	A1	UNIVERSITE DE MONTREAL et al.	04-12-2001		
	A4	wo	96/07431	A1	UNIVERSITE DE MONTREAL et al.	03-14-1996		
	A5	wo	96/31237	A1	WOUND HEALING OF OKLAHOMA	10-10-1996		
	A6	wo	99/47162	A1	WOUND HEALING OF OKLAHOMA	09-23-1999		
	A7	wo	98/07436	A1	VASOGEN INC.	02-26-1998		
	A8	wo	97/37654	A1	THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA	10-16-1997		
	A9	wo	97/36634	A1	THERAKOS, INC.	10-09-1997		

Examiner Signature	Date Considered	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. 2See attached Kinds of U.S. Patent Documents. 3Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

MODIFIED PTO/SB/08 (08-00) Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control

Tullibel.							
	Substitute fo	or form 1449B	/PTO	Complete if Known / CO1710			
	INFORMATI	ON DISCLO	SURE	Application Number	Unassigne U1301110		
	STATEMEN	T BY APPLI	CANT	Filing Date	Herewith		
	Data Cubasi		2006	First Named Inventor	Denis Claude ROY et al.		
	Date Submi	ilea: June 5,	, 2006	Group Art Unit	Carefur 0 05 Jun 2006 —		
	(use as many s	sheets as ne	cessary)	Examiner Name	Unassigned		
Sheet	2	of	2	Attorney Docket Number	029049.57806US		

NON PATENT LITERATURE DOCUMENTS							
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶				
	A10	BRASSEUR et al., "Eradication of Multiple Myeloma and Breast Cancer Cells by TH9402-mediated Photodynamic Therapy: Implication for Clinical <i>Ex Vivo</i> Purging of Autologous Stem Cell Transplants," Photochemistry and Photobiology, 2000, pp. 780-787, Vol. 72, No. 6, American Society for Photobiology					
	A11	GUIMOND et al., "P-glycoprotein targeting: a unique strategy to selectively eliminate immunoreactive T cells," <u>Blood</u> , 15 July 2002, pp. 375-382, Vol. 100, No. 2, The American Society of Hematology					
	A12	CHEN et al., "Prevention of graft-versus-host disease while preserving graft-versus-leukemia effect after selective depletion of host-reactive T cells by photodynamic cell purging process," <u>Blood</u> , 1 May 2002, Vol. 99, No. 9					
	-						
		·					

Examiner Signature	Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.